Fluzone Tiv Sh 2026 Injection, Suspension
Product Images NDC 49281-626

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Fluzone Tiv Sh 2026 (NDC 49281-626). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi Vaccines Us Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Principal Display Panel (0.5 mL Syringe Label)

Principal Display Panel (0.5 mL Syringe Label)
This text is a description of an influenza vaccine called Fluzone® for the Southern Hemisphere. It is a single-dose vial containing 0.5 mL without any preservatives for intramuscular use. The manufacturer is Sanofi Pasteur Inc.*
FDA Label Image

Principal Display Panel (0.5 mL Syringe Carton)

Principal Display Panel (0.5 mL Syringe Carton)
This text describes an influenza vaccine manufactured by Sanofi Pasteur Inc. under US Govt License #1725. The vaccine is named Fluzone 2025 Formula for the Southern Hemisphere. It is intended for intramuscular use and comes in single-dose prefilled syringes. The vaccine is stored at 2° to 8°C and should not be frozen. It is made from influenza viruses in chicken eggs and inactivated with formaldehyde. The vaccine contains no preservatives or natural rubber latex. It is standardized for the 2025 influenza season and includes 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. The vaccine includes strains representative of AlVictoria/4897/2022, A/Croatia/10136RV/2023, and B/Michigan/01/2021.*
FDA Label Image

Principal Display Panel (5 mL Vial Label)

Principal Display Panel (5 mL Vial Label)
Description: This is a 5 mL Multi-Dose Vial of Influenza Vaccine for the 2025 formula designed for the Southern Hemisphere. It contains a preservative and should not be frozen; store between 2°C to 8°C. The vaccine is for intramuscular use and comes in a 0.25 mL or 0.5 mL dose for ages 6 months to 35 months, and a 0.5 mL dose for 3 years of age and older. The packaging includes a US Govt License number 1725 and the manufacturer is Sanofi Pasteur Inc. The vial must be shaken well before use. For further details, consult the package insert.*
FDA Label Image

Principal Display Panel (5 mL Vial Carton)

Principal Display Panel (5 mL Vial Carton)
This text is a detailed description of the Southern Hemisphere Influenza Vaccine - Fluzone® for individuals aged 6 months and older. It includes information about dosage for different age groups, preparation method, preservatives used, storage instructions, standardization, and the specific strains included in the vaccine. It emphasizes not freezing the vaccine and provides details about the proprietary formula and its composition.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.